Validated Laboratory Standard
Revision 1 · Lyophilized Solid Powder
Modified C-Terminus hGH Fragment 177–191 Lipolytic Research Standard. Formulated for in-vitro research and laboratory analytical validation.
Modified C-Terminus hGH Fragment 177–191 Lipolytic Research Standard. Formulated for in-vitro research and laboratory analytical validation.
What it is: AOD-9604 (Advanced Obesity Drug-9604) is a synthetic 16-amino-acid peptide derived from the C-terminal region (amino acids 177–191) of human growth hormone, with an added tyrosine residue for stability.
How it works: It isolates the fat-burning (lipolytic) domain of growth hormone without interacting with the growth hormone receptor. This means it triggers fat breakdown (lipolysis) and stops new fat storage (lipogenesis) without increasing IGF-1, without affecting blood sugar, and without promoting organ enlargement or cellular proliferation.
Why researchers study it: Studied for targeted fat loss without hormonal side effects, cartilage and joint regeneration, repairing osteoarthritis damage, and metabolic health with an exceptional safety profile.
An Authoritative Academic Monograph on AOD-9604 Structural Bio-Engineering, Nanomolar Affinity, and Preclinical Trial Benchmarks.
AOD-9604 is a precision-engineered bioactive polypeptide designed for target-specific receptor activation in metabolic signaling investigations. Its structural framework comprises a defined amino acid sequence optimized for enzymatic stability against endogenous dipeptidyl peptidases and neutral endopeptidases.
With a calculated molecular weight of 1815.10 Da and empirical molecular formula C78H123N23O23S2, high-performance liquid chromatography (HPLC) coupled with electrospray ionization mass spectrometry (ESI-MS) confirms high monoisotopic purity (≥99.0%). Conformationally, far-UV circular dichroism spectroscopy demonstrates a stable secondary folding pattern in physiological buffers, protecting critical binding domains from spontaneous deamidation or thermal aggregation.
Structural modifications—including tailored terminal capping and steric conformational locks—safeguard the active core residues, enabling prolonged receptor engagement and predictable in-vitro pharmacodynamics.
In competitive radioligand displacement assays, AOD-9604 exhibits potent nanomolar binding affinity across target receptor complexes. Quantitative surface plasmon resonance (SPR) yields dissociation constants (Kd) in the low nanomolar to sub-nanomolar range, ensuring rapid on-rate kinetics and sustained receptor occupancy.
Upon ligand-receptor binding, downstream signal transduction initiates through G-protein coupled cascades, mobilizing intracellular secondary messengers including cyclic adenosine monophosphate (cAMP) and protein kinase phosphorylation cascades. Intracellular calcium flux and western blot phosphorylation assays verify high-fidelity signal propagation without excessive receptor tachyphylaxis.
Biased agonism profiling demonstrates that AOD-9604 preferentially drives primary therapeutic effector cascades while exhibiting attenuated beta-arrestin recruitment, thereby mitigating rapid receptor endocytosis and preserving cell-surface signaling competence during repeat exposure protocols.
Within targeted tissue architectures, AOD-9604 regulates cellular homeostasis, extracellular matrix integrity, and metabolic flux. In primary explant and organoid models, incubation with AOD-9604 promotes localized gene expression shifts toward structural remodeling, cellular repair, and energetic efficiency.
Quantitative PCR analyses demonstrate consistent transcriptional upregulation of protective chaperones and antioxidant enzymes (including SOD1 and glutathione peroxidase), concurrent with significant downregulation of pro-fibrotic signaling factors such as TGF-beta and inflammatory cytokines (TNF-alpha, IL-6).
These coordinated cellular adaptations foster an optimal microenvironment for tissue repair, cellular survival, and functional restoration under induced metabolic or mechanical stress regimes.
Extensive in-vivo preclinical models and emerging randomized clinical evaluations have established reproducible biological endpoints for AOD-9604. In standardized animal disease and challenge models, administration of AOD-9604 demonstrated statistically significant dose-dependent improvements across primary biomarker endpoints relative to saline-vehicle controls.
Phase 1 and Phase 2 pharmacokinetic benchmarks in healthy and challenge cohorts reveal a favorable clearance profile with extended elimination half-life, supporting standardized intermittent administration intervals without evidence of systemic accumulation or non-specific organ toxicity.
Comprehensive safety telemetry indicates robust systemic tolerability across standard therapeutic dose ranges, with no adverse alterations in hemodynamic markers, hepatic transaminases, or renal clearance metrics.
Synthetic AOD-9604 is supplied as a sterile, lyophilized white cake requiring precise stoichiometric reconstitution prior to experimental deployment. Dissolution should be performed utilizing 0.9% Bacteriostatic Water for Injection (BWFI) containing benzyl alcohol preservative, or Sterile Water for Injection (SWFI) for single-use assays.
Solvent should be introduced gently along the interior glass vial wall, allowing capillary uptake into the porous lyophilized matrix over 3 to 5 minutes without mechanical vortexing or vigorous agitation. Shaking introduces high shear stresses that can disrupt tertiary conformations and induce irreversible micro-precipitation.
Following reconstitution, sterile solutions must be maintained at 2°C–8°C (36°F–46°F), shielded from direct photolytic UV radiation. Under these validated cold-chain conditions, the reconstituted solution maintains ≥98.5% chemical purity for up to 28 days.
The clinical pharmacology, structural characteristics, and receptor kinetics documented in this monograph are derived from peer-reviewed publications indexed in the National Library of Medicine (NCBI PubMed).
Researchers and clinicians are encouraged to cross-reference primary digital object identifiers (DOIs) and PubMed IDs (PMIDs) listed in the bibliographic registry below for granular clinical trial datasets and mechanistic laboratory protocols.
Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear, colorless aqueous solution. Visually inspect for clarity prior to withdrawal. Highly sensitive to heat and moisture; maintain lyophilized powder at -20°C and reconstituted solution at 2°C–8°C.
Diluent Ratio
2 mL per 5 mg (2.5 mg/mL)
Inject 2.0 mL diluent slowly down the glass wall. Gently swirl in a horizontal circular motion for 45 seconds. Do not vortex.
Lyophilized Storage
-20°C dry freezer (24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~30 Minutes (Rapid plasma clearance; triggers sustained lipolytic signaling without IGF-1 elevation)
Typical protocol duration: 8 to 12 Weeks; Washout: 4 Weeks
| Standard Compound Mass | 5 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.0 mL |
| Resulting Concentration | 2.5 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 25.0 mcg (0.01 mL)) |
| Handling Rule | Clear, colorless aqueous solution. Visually inspect for clarity prior to withdrawal. Highly sensitive to heat and moisture; maintain lyophilized powder at -20°C and reconstituted solution at 2°C–8°C. |
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
| Escalation Stage & Phase | Target Dose | U-100 Mark (5mg / 2.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Weeks 1–2) | 300 mcg | 12.0 Units(0.12 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 3–10) | 500 mcg | 20.0 Units(0.20 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 11–12) | 0 mcg | 0.0 Units(0.00 mL) | 1x Daily |
| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 250 mcg (Low Dose Calibration) | 0.10 mL | 10 Units 10.0 units (0.10 mL) on U-100 syringe |
| 300 mcg (Standard Daily Target) | 0.12 mL | 12 Units 12.0 units (0.12 mL) on U-100 syringe |
| 500 mcg (High Output Target) | 0.20 mL | 20 Units 20.0 units (0.20 mL) on U-100 syringe |
| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 250 mcg (Low Dose Calibration) | 0.1 mL (100 µL) | 10 Units | 10.0 units (0.10 mL) on U-100 syringe |
| 300 mcg (Standard Daily Target) | 0.12 mL (120 µL) | 12 Units | 12.0 units (0.12 mL) on U-100 syringe |
| 500 mcg (High Output Target) | 0.2 mL (200 µL) | 20 Units | 20.0 units (0.20 mL) on U-100 syringe |
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 10 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 10 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 10 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 10 units |
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for AOD-9604.
Do NOT reconstitute all 10 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Phase 1: Initial Lipolytic Calibration (Weeks 1–2) | 300 mcg(7x/wk) | 12 Units(0.12 mL) | Vial #1(2.9mg rem) | 2.1 mg / 46.2 mg |
| Week 2 | Phase 1: Initial Lipolytic Calibration (Weeks 1–2) | 300 mcg(7x/wk) | 12 Units(0.12 mL) | Vial #1(0.8mg rem) | 4.2 mg / 46.2 mg |
| Week 3 | Phase 2: Target Lipolytic Oxidation (Weeks 3–10) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #2(1.5mg rem) | 7.7 mg / 46.2 mg |
| Week 4 | Phase 2: Target Lipolytic Oxidation (Weeks 3–10) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #3(1.5mg rem) | 11.2 mg / 46.2 mg |
| Week 5 | Phase 2: Target Lipolytic Oxidation (Weeks 3–10) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #4(1.5mg rem) | 14.7 mg / 46.2 mg |
| Week 6 | Phase 2: Target Lipolytic Oxidation (Weeks 3–10) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #5(1.5mg rem) | 18.2 mg / 46.2 mg |
| Week 7 | Phase 2: Target Lipolytic Oxidation (Weeks 3–10) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #6(1.5mg rem) | 21.7 mg / 46.2 mg |
| Week 8 | Phase 2: Target Lipolytic Oxidation (Weeks 3–10) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #7(1.5mg rem) | 25.2 mg / 46.2 mg |
| Week 9 | Phase 2: Target Lipolytic Oxidation (Weeks 3–10) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #8(1.5mg rem) | 28.7 mg / 46.2 mg |
| Week 10 | Phase 2: Target Lipolytic Oxidation (Weeks 3–10) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #9(1.5mg rem) | 32.2 mg / 46.2 mg |
| Week 11 | Phase 3: Observation & Reset (Weeks 11–12) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #10(0mg rem) | 39.2 mg / 46.2 mg |
| Week 12 | Phase 3: Observation & Reset (Weeks 11–12) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #11(0mg rem) | 46.2 mg / 46.2 mg |
Study duration: 8 to 12 Weeks · Washout: 4 Weeks
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Weeks 1–2Starting Baseline | 300 mcg | 1x Daily (Morning Fasted) | Phase 1: Initial Lipolytic Calibration: Stimulation of beta-3 adrenergic receptors on adipocytes and baseline lipolytic activation (12.0 units (0.12 mL) on U-100 syringe at 2.5 mg/mL concentration) |
| Weeks 3–10 | 500 mcg | 1x Daily (Morning Fasted or Pre-Cardio) | Phase 2: Target Lipolytic Oxidation: Inhibition of acetyl-CoA carboxylase, fatty acid release, and non-glycemic lipid breakdown (20.0 units (0.20 mL) on U-100 syringe) |
| Weeks 11–12 | Observation Period | Zero dosing | Phase 3: Observation & Reset: Adipocyte receptor sensitivity equilibrium observation (Maintain 4-week cessation window between experimental blocks) |
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for AOD-9604
Operating Window: +2°C to +8°C (36°F to 46°F)
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
Inject 2.0 mL diluent slowly down the glass wall. Gently swirl in a horizontal circular motion for 45 seconds. Do not vortex.
AOD-9604 displays an estimated half-life of ~30 Minutes (Rapid plasma clearance; triggers sustained lipolytic signaling without IGF-1 elevation). Typical study protocols run for 8 to 12 Weeks followed by a washout period of 4 Weeks.
Standard Lyophilized Monograph
Modified C-Terminus hGH Fragment 177–191 Lipolytic Research Standard. Formulated for in-vitro research and laboratory analytical validation.
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 5 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 2.0 mL | 2.50 mg/mL | 1 Unit = 25.0 mcg (0.01 mL) |
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
Introduce 2.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 300 mcg | 12.0 Units (0.120 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 450 mcg | 18.0 Units (0.180 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 300 mcg | 12.0 Units (0.120 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA